Activating anti-CD40 antibody partially mitigates the deficit in CTL generation and accumulation elicited by immunization with F/T 4T1-OVA cells. Activating.

Slides:

Advertisements

Similar presentations

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Advertisements

Cheng-Ming Sun, Edith Deriaud, Claude Leclerc, Richard Lo-Man Immunity

Volume 17, Issue 9, Pages (September 2009)

Volume 44, Issue 2, Pages (February 2016)

Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine Weiqing Jing,

Tatsukuni Ohno, Yuta Kondo, Chenyang Zhang, Siwen Kang, Miyuki Azuma

Volume 24, Issue 11, Pages (November 2016)

Volume 15, Issue 2, Pages (February 2007)

by Norman Nausch, Ioanna E

Initial T Cell Receptor Transgenic Cell Precursor Frequency Dictates Critical Aspects of the CD8+ T Cell Response to Infection Vladimir P. Badovinac,

Insulin-like growth factor 2 enhances regulatory T-cell functions and suppresses food allergy in an experimental model Gui Yang, MD, Xiao-Rui Geng, MD,

Volume 31, Issue 2, Pages (August 2009)

Volume 31, Issue 5, Pages (November 2009)

Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy by Fumihiko Tsushima, Sheng Yao, Tahiro Shin, Andrew Flies, Sarah.

Volume 11, Issue 12, Pages (June 2015)

Volume 42, Issue 2, Pages (February 2015)

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Volume 18, Issue 5, Pages (May 2003)

Volume 11, Issue 5, Pages (November 1999)

Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor Responses William H.D. Hallett, Erik Ames, Maite.

Volume 25, Issue 1, Pages (January 2014)

Skin-Derived Dendritic Cells Induce Potent CD8+ T Cell Immunity in Recombinant Lentivector-Mediated Genetic Immunization Yukai He, Jiying Zhang, Cara.

Volume 33, Issue 6, Pages (December 2010)

IFN-γ induces TNF family ligand protein expression in vitro and in vivo. IFN-γ induces TNF family ligand protein expression in vitro and in vivo. (A and.

Volume 29, Issue 6, Pages (December 2008)

Volume 20, Issue 3, Pages (March 2004)

Interleukin-18 and the Costimulatory Molecule B7-1 Have a Synergistic Anti-Tumor Effect on Murine Melanoma; Implication of Combined Immunotherapy for.

Volume 25, Issue 4, Pages (April 2017)

Volume 6, Issue 6, Pages (December 2009)

by Frank M. Szaba, and Stephen T. Smiley

CD8+ Cytotoxic T Cells Induce Relapsing Colitis in Normal Mice

Volume 34, Issue 3, Pages (March 2011)

Volume 38, Issue 3, Pages (March 2013)

CD301b+ Dermal Dendritic Cells Drive T Helper 2 Cell-Mediated Immunity

Eric A Butz, Michael J Bevan Immunity

CTLA-4 Regulates Induction of Anergy In Vivo

Volume 41, Issue 1, Pages (July 2014)

Volume 24, Issue 1, Pages (January 2016)

Volume 38, Issue 3, Pages (March 2013)

In Vivo Expansion of Regulatory T cells With IL-2/IL-2 mAb Complexes Prevents Anti- factor VIII Immune Responses in Hemophilia A Mice Treated With Factor.

Karima R.R. Siddiqui, Sophie Laffont, Fiona Powrie Immunity

Arp2/3-mediated formation of nuclear actin networks is essential for CD4+ T cell effector functions. Arp2/3-mediated formation of nuclear actin networks.

Volume 21, Issue 1, Pages (January 2017)

Volume 12, Issue 2, Pages (July 2015)

Epicutaneous Application of CpG Oligodeoxynucleotides with Peptide or Protein Antigen Promotes the Generation of CTL Sandra K. Klimuk, Hossain M. Najar,

Antigen-Specific Suppression of a Primed Immune Response by Dendritic Cells Mediated by Regulatory T Cells Secreting Interleukin-10 Ela Martin, Brendan.

Fig. 4 The PTEN pathway in Tregs is required to suppress immune responses to apoptotic cells. The PTEN pathway in Tregs is required to suppress immune.

Volume 31, Issue 5, Pages (November 2009)

Volume 20, Issue 3, Pages (March 2012)

Volume 25, Issue 4, Pages (April 2017)

Volume 38, Issue 3, Pages (March 2013)

The Coinhibitory Receptor CTLA-4 Controls B Cell Responses by Modulating T Follicular Helper, T Follicular Regulatory, and T Regulatory Cells Peter T.

Volume 35, Issue 1, Pages (July 2011)

Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but not OVA Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but.

Engagement of the Type I Interferon Receptor on Dendritic Cells Inhibits T Helper 17 Cell Development: Role of Intracellular Osteopontin Mari L. Shinohara,

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

Volume 17, Issue 6, Pages (December 2002)

Volume 13, Issue 11, Pages (December 2015)

CD4+ cells are required to generate protective immunity against the MT-HA tumor in HA104 mice. CD4+ cells are required to generate protective immunity.

Cross-presentation of ova to ova-specific CD8+ T cells in vivo by ova-loaded gp96 surface-expressing tumor cells. Cross-presentation of ova to ova-specific.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

The effect of TGFβ on the post-RT increase of Tregs in tumors.

Immune response of CEA-transgenic mice transferred with OT-1 splenocytes and immunized with ovalbumin and adjuvant. Immune response of CEA-transgenic mice.

Anti–TGF-β1 antibody neutralizes APB-mediated immune suppression.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

The effect of βAR signaling on the generation of a cytotoxic CD8+ T-cell response in vivo. The effect of βAR signaling on the generation of a cytotoxic.

Immunization with F/T cells elicits CTLs with moderate and transient effector function. Immunization with F/T cells elicits CTLs with moderate and transient.

Immunization with IR or F/T 4T1-OVA cells elicits similar numbers of APCs capable of cross-presenting antigen. Immunization with IR or F/T 4T1-OVA cells.

Immunization with IR or F/T elicits activated OT-I cells of distinct phenotypes. Immunization with IR or F/T elicits activated OT-I cells of distinct phenotypes.

Presentation transcript:

Activating anti-CD40 antibody partially mitigates the deficit in CTL generation and accumulation elicited by immunization with F/T 4T1-OVA cells. Activating anti-CD40 antibody partially mitigates the deficit in CTL generation and accumulation elicited by immunization with F/T 4T1-OVA cells. (A) Groups of C57BL/6 mice were adoptively transferred with 2.5×105 OT-I T cells 1 d prior to immunization with IR or F/T 4T1-OVA cells. Twenty-four hours post-immunization, mice received an injection of 150 μg of activating anti-CD40 antibody or isotype control antibody. Six days following immunization, all mice were adoptively transferred with target cells and a CTL assay in vivo was performed. Data are shown as the mean specific killing 20 h post-immunization. One of three experiments is shown and error bars represent SD of triplicate samples. (B) Immunization with F/T 4T1-OVA cells followed by anti-CD40 antibody injection increases OT-I T cell accumulation in the DLNs. Mice were treated according to panel A. Six days post-immunization, DLNs were harvested and the absolute number of OT-I cells was determined. Data is shown as the mean (±SD) of triplicate samples. (C) Blocking CD40/CD40L interactions diminishes OT-I accumulation elicited by immunization with IR 4T1-OVA cells. Groups of C57BL/6 mice received 106 OT-I cells 1 d prior to immunization with PBS or IR 4T1-OVA cells. At the indicated time points post-immunization, groups were treated i.v. with 200 μg of MR1 (anti-CD154, CD40L) blocking antibody. Six days post-immunization DLNs were analyzed for OT-I accumulation. Matthew R. Buckwalter, and Pramod K. Srivastava Cancer Immun 2013;13:2 Copyright © 2013 by Pramod K. Srivastava